GlassScriptPhysician profile
Lawrence Alan Berger
NPI 1649442740
$6,332.33
in general payments reported to CMS, 2019-2025
33 companies · $915 in 2025
The $915 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $537 · 2021: $791 · 2022: $854 · 2023: $1,232 · 2024: $899 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,045.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,106.22 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $940.23 | 2019-2025 | |
| Lilly USA, LLC | $400.78 | 2019-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $388.10 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $387.72 | 2019-2024 | Xarelto |
| Heartflow, INC. | $346.92 | 2022-2024 | Ffrct |
| Amgen INC. | $310.58 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $285.38 | 2019-2024 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $266.52 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $235.26 | 2021-2024 | Proclaim, Eterna, Freestyle Libre |
| Amarin Pharma, INC. | $182.11 | 2019-2021 | |
| Cleerly, INC. | $166.40 | 2025 | Cleerly Ischemia, Cleerly Labs |
| Otsuka America Pharmaceutical, INC. | $165.58 | 2023 | Rexulti |
| Sunovion Pharmaceuticals INC. | $150.36 | 2019-2021 | |
| Glaxosmithkline, LLC. | $135.13 | 2019-2023 | Trelegy Ellipta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.63 | 2019-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $106.65 | 2024 | |
| Idorsia Pharmaceuticals US INC | $91.09 | 2022-2023 | Quviviq |
| Arbor Pharmaceuticals, INC. | $79.67 | 2019-2021 | |
| Exact Sciences Corporation | $71.91 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $69.15 | 2021-2022 | |
| Esperion Therapeutics, INC. | $54.04 | 2024-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $51.88 | 2020-2021 | |
| Abbvie INC. | $37.20 | 2020-2023 | Linzess, Viberzi |
| Sanofi-Aventis U.S. LLC | $34.27 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.71 | 2025 | |
| Sumitomo Pharma America, INC. | $20.91 | 2023 | Gemtesa |
| Sanofi Pasteur INC. | $20.74 | 2021 | |
| Eisai INC. | $20.42 | 2025 | |
| Sun Pharmaceutical Industries INC. | $18.75 | 2022 | |
| Ibsa Pharma INC. | $18.69 | 2022 | |
| Hikma Pharmaceuticals USA | $14.49 | 2023 | Mitigare, Ryaltris |
| Currax Pharmaceuticals LLC | $13.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.